SURMOUNT-1 tested three once-weekly subcutaneous tirzepatide target doses against placebo over 72 weeks.
Claim:
In the Phase 3 SURMOUNT-1 trial, participants received once-weekly subcutaneous tirzepatide at doses of 5 mg, 10 mg, or 15 mg, or placebo, for 72 weeks.
NOT BS